Matthew J. Matasar, MD

home / authors / matt-matasar-md

Matthew J. Matasar, MD, is a hematologist/oncologist and chief, Division of Blood Disorders, at the Rutgers Cancer Institute, as well as a professor of medicine at Rutgers Robert Wood Johnson Medical School.

Articles

Experts on FL

An Overview on the Nature of Follicular Lymphoma

Matthew J. Matasar, MD;Laurie Sehn, MD
December 2nd 2022

Opening their discussion on follicular lymphoma, experts Matthew Matasar, MD and Laurie Sehn, MD, reflect on its indolent nature as a subset of non-Hodgkin lymphoma.

Loncastuximab Shows Durable Response in Higher-Risk R/R DLBCL Population

Loncastuximab Shows Durable Response in Higher-Risk R/R DLBCL Population

Matthew J. Matasar, MD
August 5th 2022

Matthew J. Matasar, MD, discusses the LOTIS-2 trial of loncastuximab tesirine in patients with relapsed/refractory diffuse large B-cell lymphoma.

Changes in the Treatment Landscape for Patients With DLBCL

Changes in the Treatment Landscape for Patients With DLBCL

Matthew J. Matasar, MD
June 1st 2022

Matthew J. Matasar, MD, discusses the current landscape of diffuse large B-cell lymphoma.

New Treatment Regimen Examined in POLARIX Trial for Patients With DLBCL

New Treatment Regimen Examined in POLARIX Trial for Patients With DLBCL

Matthew J. Matasar, MD
April 16th 2022

Matthew J. Matasar, MD, discusses how updates in the diffuse large B-cell lymphoma field have led to improved quality of life in patients.

Matasar Considers Treatment Options in B-Cell Lymphoma

Matasar Considers Treatment Options in B-Cell Lymphoma

Matthew J. Matasar, MD
September 29th 2021

Matt Matasar, MD, discusses treatment options in B-cell lymphomas.

<12

Latest Updated Articles

ASH 2024 Preview for Community Oncologists: The Show and After Show
Published: December 3rd 2024 | Updated: December 6th 2024
ASH 2024 Preview for Community Oncologists: The Show and After Show
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Starting Therapy for Intermediate-Risk Myelofibrosis Based on Hemoglobin
Published: April 28th 2025 | Updated: May 19th 2025
Starting Therapy for Intermediate-Risk Myelofibrosis Based on Hemoglobin
Optimizing CAR T-Cell Therapy Prep in Multiple Myeloma After Relapse
Published: April 24th 2025 | Updated: May 19th 2025
Optimizing CAR T-Cell Therapy Prep in Multiple Myeloma After Relapse
Participants Explain Rationale for Different IO/TKI Options for ccRCC
Published: April 15th 2025 | Updated: May 19th 2025
Participants Explain Rationale for Different IO/TKI Options for ccRCC
FDA Accepts sBLA for Pembrolizumab Monotherapy for Endometrial Cancer
Published: August 10th 2021 | Updated: May 19th 2025
FDA Accepts sBLA for Pembrolizumab Monotherapy for Endometrial Cancer